06:41 AM EDT, 08/09/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) reported Q2 adjusted earnings Friday of $0.16 per diluted share, down from $0.19 a year earlier.

Four analysts polled by Capital IQ expected $0.14.

Net revenue for the quarter ended June 30 was $701.8 million, up from $599 million a year earlier.

Three analysts polled by Capital IQ expected $657.5 million.

For 2024, the company now expects adjusted diluted EPS of $0.57 to $0.63, narrowing its previous guidance of $0.53 to $0.63. It also raised its revenue guidance for the full year to $2.7 billion to $2.8 billion, from $2.55 billion to $2.65 billion.

Analysts surveyed by Capital IQ are looking for adjusted EPS of $0.61 on revenue of $2.64 billion.

Price: 7.70, Change: -0.07, Percent Change: -0.90